Literature DB >> 30261847

Correction to: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.

Shuhui Cui1, Ruoyan Gai Tobe2,3, Xiuting Mo1, Xiaoyan Liu1, Lingzhong Xu1, Shixue Li1.   

Abstract

After the publication of our article [1] we have been made aware of a number of mislabelling and reporting errors, which were introduced in the preparation of the manuscript. The conclusions are not affected by these errors and thus remain unchanged.

Entities:  

Year:  2018        PMID: 30261847      PMCID: PMC6161355          DOI: 10.1186/s12879-018-3370-8

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Correction

After the publication of our article [1] we have been made aware of a number of mislabelling and reporting errors, which were introduced in the preparation of the manuscript. The conclusions are not affected by these errors and thus remain unchanged.

The corrections required are as follows

Correction 1

In the Methods section under the heading “Vaccine effectiveness”, the sentence: “The protection effectiveness of Rotarix and Rotateq were derived from randomized controlled trials in other Asian regions such as Hong Kong, Taiwan and Singapore, considering the ethnic homogeneity [25], because there was no eligible data specifically for the Chinese population.” has been corrected to: “The protection effectiveness of Rotarix and Rotateq were derived from randomized controlled trials [25] and clinical reviews cited by economic evaluation studies in other Asian regions such as Hong Kong, Taiwan and Singapore, due to no eligible data specifically for the Chinese population.”

Correction 2

In the Results section under the heading “Health impacts and cost-effectiveness of vaccination”, the sentence: “The total cost is even less than non-vaccination.” has been corrected to: “The ACER is even less than non-vaccination.”

Correction 3

Four corrections are required to Table 1 as follows: Rotateq efficacy: the plausible range for sensitivity analysis “0 - 0.98” has been corrected to “0.883 - 1”; Source “38” has been corrected to “38, 42”. “Mortality rate” under the heading “Parameters” has been removed as it appeared twice in the Table. Costs for international vaccinations: the plausible range for sensitivity analysis “5 - 250” has been corrected to “50 - 250” Infection rate: Source: “34” has been corrected to “21, 45”. A corrected version of Table 1 appears below.

Correction 4

The values presented in Table 2 were mislabelled and incorrectly shown. The correct version of Table 2 is shown below. Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no intervention

Correction 5

The axes in Figure 2 were mislabelled. The correct version of Figure 2 is shown below. Cost-effectiveness of rotavirus vaccines at the baseline

Correction 6

The following reference should be included in the reference list: 45. Wu J, Yao Y, Hao W. Clinical Epidemiological Study on 244 Cases of Neonatal Rotavirus Infection. Chin J Nosocomiol, 1999, 9(4): 228–29 (in Chinese).
Table 1

BaselinePlausible range for sensitivity analysisSources
Parameters
 Discount rate0.0300.03[31]
 Vaccine coverage25.3%10%28.6%[36, 37]
 Mortality rate0.0058%0.0000290.000039[41]
 Rotateq efficacy98%0.8831[38, 42]
 Rotateq infected0.018%00.00018[42]
 hospitalization1a44%00.44[22]
 Outpatient1 a28%00.28[22]
 Home-care1 a28%00.28[22]
 Rotarix infected0.1%00.001[26]
 LLR infected0.9%00.009[41]
 hospitalization3c0.2%00.002[2]
 Outpatient3 c7.9%00.079[2]
 home-care3 c91.9%00.919[2]
 Rotarix efficacy96.1%0.8711[25, 26]
 LLR efficacy72%0.630.79[27]
 Infection rate78.85%00.7885[21, 45]
 home-care2b32%00.32[22]
 hospitalization2 b33%00.33[22]
 Outpatient2 b35%00.35[22]
 natural protact1d77%00.77[23]
 natural protact2 d83%00.83[23]
Costs
 International vaccinations200.0050250[16, 17]
 LLR vaccination24The national tariff
 Hospitalizations570.040570.04[43]
 Outpatient104.190104.19[43]
 Home-care11.52011.52[44]
Health Effects
 QALY(Hospitalization)0.0770.0750.078[30]
 QALY(Outpatient)0.08100.081[30]
 QALY(Home-care)0.08200.082[30]
Table 2

Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no intervention

Strategy NameCostQALYsIncremental cost-effectiveness ratio ($/QALY)
No vaccine2379.94517.71296(−)
LLR vaccine2507.85122.658990
Rotarix vaccination5982.18724.314542105.66
Rotateq vaccination5577.90224.445061715.14
  1 in total

1.  Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.

Authors:  Shuhui Cui; Ruoyan Gai Tobe; Xiuting Mo; Xiaoyan Liu; Lingzhong Xu; Shixue Li
Journal:  BMC Infect Dis       Date:  2016-11-15       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.